Pseudomonas aeruginosa

ContraFect to Present at the SVB Leerink 11th Annual Global Healthcare Conference

Retrieved on: 
Thursday, February 10, 2022
GLOBE, Maintenance, Trial of the century, U.S. Securities and Exchange Commission, Osteomyelitis, Death, Subclinical infection, Conference, Pseudomonas aeruginosa, Investor, Infection, DLA, Clinical trial, SVB, SOC, FDA, Bacteria, MRSA, Lysin, Security (finance), Enterobacter, Biofilm, Acinetobacter baumannii, Campaign, Endocarditis, Nasdaq, Pneumonia, Breakthrough therapy, Peptide, Forward-looking statement, Pharmaceutical industry

A live webcast of the event will be available on the Investors & Media section of the Companys website at www.contrafect.com .

Key Points: 
  • A live webcast of the event will be available on the Investors & Media section of the Companys website at www.contrafect.com .
  • It will also be available as an archived webcast for a limited time.
  • ContraFect is a biotechnology company focused on the discovery and development of DLAs, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections.
  • We intend to address life threatening infections using our therapeutic product candidates from our platform of DLAs, which include lysins and amurin peptides.

New Austere "V Series" Clean & Protect™ Solution Fights Germs and Keeps All Home Electronics and Mobile Devices Spotless and Safe

Retrieved on: 
Tuesday, January 25, 2022
Amazon (company), Candida albicans, P. C. Richard & Son, Technology, Pseudomonas aeruginosa, Conn's, Bacterial leaf streak, Homeplus, Escherichia coli, Abt Electronics, Vision Electronic Recording Apparatus, Virus, Philosophy, Protection, CEO, Government, Instagram, Electronics, Bacteria, Television, Facebook, Clean, Twitter, Life, Investment, Toy, Pneumonia, Austerity (disambiguation), Coronavirus

Austere's Clean & Protect comes with a 6.7-inch x 6.7-inch special dual-textured cloth to clean and buff screens.

Key Points: 
  • Austere's Clean & Protect comes with a 6.7-inch x 6.7-inch special dual-textured cloth to clean and buff screens.
  • Deena Ghazarian, CEO & Founder, Austere notes: "When developing Austere's Clean & Protect we wanted to help our customers protect and enjoy all of their electronics investments.
  • The combination of Austere's Clean & Protect solution and our double-sided cloth ensures a perfect result every time"
    The ammonia-free Austere V Series Clean & Protect solution offers users the sameactive germicidal formula to eliminate common bacteria, viruses, and mold as the original Clean & Protect.
  • At this time, Austere Clean & Protect has not been tested on Coronavirus (2019-nCoV) due to government regulations, but we will expand our testing when available.

Eagle Protect Sounds Alarm on Supply Chain Contamination

Retrieved on: 
Wednesday, January 19, 2022
Supply Chain Management, Restaurant, Bar, General Health, Supermarket, Infectious Diseases, Food, Beverage, Other Manufacturing, Retail, Chemicals, Plastics, Medical Supplies, Manufacturing, Health, Meat, Anthrax, IAFP, Ernst & Young, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Streptococcus pneumoniae, International Food Protection Training Institute, Environmental impact of meat production, Bacillus anthracis, Food, Protection, Safety, CEO, LLP, Part, Bacillus cereus, Â, Food safety, GMA, Health, PPE, Office of Inspector General, U.S. Department of Health and Human Services, Industry, Covington & Burling, Staphylococcus aureus, Eagle, Food industry, Risk, Trust, FDA, Pseudomonas aeruginosa, International Association, Bald and Golden Eagle Protection Act, Listeria monocytogenes, Medical device, Bacillus

Eagle Protects findings, combined with the meat recall notice, has prompted the company to issue an urgent warning to the food handling industry on the hidden risks of not just chemical but also significant microbial single-use glove contamination in the existing supply chain.

Key Points: 
  • Eagle Protects findings, combined with the meat recall notice, has prompted the company to issue an urgent warning to the food handling industry on the hidden risks of not just chemical but also significant microbial single-use glove contamination in the existing supply chain.
  • In the case of food recalls, the key concern which needs to be addressed is the source of contamination, said Steve Ardagh, CEO of Eagle Protect .
  • At what stage of the food supply chain is the contamination occurring?
  • Additional preventive controls are necessary to protect the food supply from glove cross-contamination.

Qpex Biopharma Announces Progress on Three Clinical Stage Programs for Antibiotic-Resistant Pathogens and Corporate Update

Retrieved on: 
Wednesday, January 19, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, CDC, Office of the Assistant Secretary for Preparedness and Response, ESBL, World Health Organization, Urinary tract infection, Acinetobacter, LinkedIn, Publication, Exercise, Aivo Orav, Office of Inspector General, U.S. Department of Health and Human Services, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Drug of last resort, Achievement, Biomedical Advanced Research and Development Authority, Human services, Assistant, Â, World, BARDA, Health, QIDP, Development, U.S. Department of Defense Strategy for Operating in Cyberspace, Infection, Program, WHO, Ventilator-associated pneumonia, Food, Twitter, Pharming, FDA, Pseudomonas aeruginosa, Partnership, OTA, Pharmaceutical industry, Pseudomonas

Qpex Biopharma, Inc. , (Qpex) a clinical-stage biopharmaceutical company discovering and developing innovative anti-infective therapies, today announced continued clinical progress of its entire pipeline and highlights the companys strategic advancements.

Key Points: 
  • Qpex Biopharma, Inc. , (Qpex) a clinical-stage biopharmaceutical company discovering and developing innovative anti-infective therapies, today announced continued clinical progress of its entire pipeline and highlights the companys strategic advancements.
  • OMNIvance (IV) and ORAvance (oral) are investigational products based on Qpexs ultra-broad-spectrum beta-lactamase inhibitor xeruborbactam (formerly known as QPX7728).
  • QIDP designation is granted by the FDA for product candidates that have the potential to treat life-threatening infections due to certain qualifying pathogens, including multi-drug resistant gram-negative pathogens.
  • The QIDP designation received by all three Qpex products include multiple potential indications, including treatment of complicated urinary tract infections and ventilator-associated pneumonia.

POWER PLATE INTRODUCES A NEW MASSAGE GUN WITH BEST-IN-CLASS TECHNOLOGY

Retrieved on: 
Tuesday, January 11, 2022
Aureus, Technology, PHS, Staphylococcus aureus, Massage, Safety, Escherichia coli, CEO, Solution, Vibration, Instagram, Movement, Health, Industry, Quality of life, Multimedia, Whole body vibration, Pulse, Twitter, Pseudomonas aeruginosa, Transformer, Klebsiella, Facebook

CHICAGO, Jan. 11, 2022 /PRNewswire/ -- Power Plate , the global leader in wholebody vibration is proud to introduce a completely upgraded Power Plate Pulse massage gun to their renowned lineup of the world's best vibration products.

Key Points: 
  • CHICAGO, Jan. 11, 2022 /PRNewswire/ -- Power Plate , the global leader in wholebody vibration is proud to introduce a completely upgraded Power Plate Pulse massage gun to their renowned lineup of the world's best vibration products.
  • The Power Plate Pulse is a powerful, yet lightweight, whisper quiet full size handheld massager designed to relax, rejuvenate, and repair muscles better than ever before.
  • "Our new Pulse is the most effective, efficient and technologically advanced massage gun available on the market," said Lee Hillman, CEO of Performance Health Systems, owner and manufacturer of Power Plate.
  • Offered in matte red and matte black, the Power Plate Pulse is now available for $199.99 at select retail locations, powerplate.com and other authorized Power Plate online retailers.

Global Infectious Diseases Partnering Analysis Report 2014-2021: Deal Trends, Players and Financials for Over 2,600 Deals - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 11, 2022
Health, Infectious Diseases, Helicobacter pylori, Anthrax, Research, Technology, Herpes simplex, Mycobacterium avium complex, Tetanus, TB, Center for Global Infectious Disease Research, Dengue fever, Respiratory syncytial virus, RSV, Campylobacter jejuni, Streptococcus, Escherichia coli, Haemophilus influenzae, MRSA, Hepatitis A, Methicillin-resistant Staphylococcus aureus, Yellow fever, Infection, HIV, Salmonella, Clostridium difficile, FIV, Common cold, Contract, African trypanosomiasis, Foot, Hyperlink, Pseudomonas aeruginosa, A-Z, Lyme disease, Vaccine, Pharmaceutical industry, Aquaculture, Malaria, Diphtheria, West Nile virus, Cytomegalovirus, Sepsis, Tuberculosis, H1N1, Haemophilus, Zika fever

The "Global Infectious Diseases Partnering 2014-2021: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Infectious Diseases Partnering 2014-2021: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
  • The Global Infectious Diseases Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for over 2,600 infectious diseases deals.
  • The report takes readers through the comprehensive Infectious Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Infectious Diseases deals.
  • In addition, a comprehensive appendix is provided with each report of all Infectious Diseases partnering deals signed and announced since 2014.

Entasis Therapeutics to Participate in H.C. Wainwright BioConnect 2022

Retrieved on: 
Monday, January 10, 2022
Infection, Enterobacteriaceae, Entasis, NASDAQ, Company, GLOBE, Wright Investors' Service Holdings, Inc., Pseudomonas aeruginosa, Vaccine

WALTHAM, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that the Company will be participating in the H.C. Wainwright BioConnect 2022 investor conference, to be held virtually from January 10-13, 2022.

Key Points: 
  • WALTHAM, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that the Company will be participating in the H.C. Wainwright BioConnect 2022 investor conference, to be held virtually from January 10-13, 2022.
  • Details for the event and managements participation are as follows:
    Format: On-demand investor presentation beginning on January 10, 1-on-1 investor meetings
    Entasis is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria.
  • Entasis pathogen-targeted design platform has produced a pipeline of product candidates, including post Phase 3 sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0462 (targeting multiple Gram-negative pathogens including Pseudomonas aeruginosa) and ETX0282CPDP (targeting Enterobacteriaceae infections).
  • For more information, visit www.entasistx.com .

ContraFect Announces Award from the Cystic Fibrosis Foundation to Evaluate Exebacase as a Potential Treatment for Serious MRSA Lung Infections Associated with Cystic Fibrosis

Retrieved on: 
Thursday, January 6, 2022
People, Subclinical infection, Trial of the century, Breakthrough therapy, CFF, Research and development, Valencia CF Foundation, Pancreas, Pseudomonas aeruginosa, Security (finance), Endocarditis, GI, FDA, Mortality, Osteomyelitis, Cystic Fibrosis Foundation, Biofilm, Hearing loss, BSI, Rockefeller University, Liver, Program, Infection, MRSA, Bacteria, Cystic fibrosis, Population, Methicillin-resistant Staphylococcus aureus, Exocrine gland, Nasdaq, Clinical trial, Hospital, Development, Forward-looking statement, Patient, Lysin, Acinetobacter baumannii, GLOBE, Risk, Acceleration, Peptide, Investor, CF, DLA, Urinary tract infection, Pneumonia, U.S. Securities and Exchange Commission, Enterobacter, SOC, Growth, Mucus, Campaign, Treating, Bloodstream infections, Maintenance, Death, Pharmaceutical industry, Antibiotics

This contract award will support investigation of the potential utility of exebacase for treating serious lung infections caused by methicillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis (CF).

Key Points: 
  • This contract award will support investigation of the potential utility of exebacase for treating serious lung infections caused by methicillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis (CF).
  • MRSA lung infections lead to potential acceleration in the decline in lung function and are an independent predictor of mortality in the CF population.
  • Chronic lung infections are known to be the main cause of lung function deterioration, and ultimately mortality, in CF patients.
  • The award from the Cystic Fibrosis Foundation will provide ContraFect with financial support for research activities.

CF Foundation Awards Up to $5 Million to BiomX for Potential Phage Therapy

Retrieved on: 
Tuesday, January 4, 2022
Research, Infectious Diseases, Clinical Trials, Philanthropy, Other Health, Biotechnology, Pharmaceutical, Health, Foundation, Science, People, Safety, Hearing loss, National, Drug of last resort, CF, Infection, Pseudomonas, Diagnosis, Risk, Clinical trial, Pseudomonas aeruginosa, Bacteria, Food, Nature, Phage therapy, Conditional sentence, Mark (given name), MD, Research, Valencia CF Foundation, Virus, Food and Drug Administration Amendments Act of 2007, Patient, Cystic Fibrosis Foundation, Bacteriophage, Investigational New Drug, Respiratory tract, Cystic fibrosis, Environment, Pharmaceutical industry, Foundation

The Foundation has supported several phage studies to explore the feasibility of phage therapy as a treatment for drug-resistant infections in CF.

Key Points: 
  • The Foundation has supported several phage studies to explore the feasibility of phage therapy as a treatment for drug-resistant infections in CF.
  • Although promising results have been reported in several individual cases, studies like this one will help us evaluate the safety and efficacy of phage as a potential therapy.
  • Rigorous clinical studies are needed to assess the safety and efficacy of phage for potential wider use in CF.
  • The Foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of Foundation support.

BiomX Announces Therapeutics Development Award of up to $5 Million from the Cystic Fibrosis Foundation

Retrieved on: 
Tuesday, January 4, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Safety, CF, CFF, Private Securities Litigation Reform Act, Conditional sentence, U.S. Securities and Exchange Commission, Mortality, Pseudomonas aeruginosa, Forward-looking statement, Company, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmacokinetics, SEC, NYSE, Therapy, Valencia CF Foundation, Patient, Cystic Fibrosis Foundation, Phage therapy, Disease, Security (finance), Part, Atopic dermatitis, Colorectal cancer, Inflammatory bowel disease, Cystic fibrosis, Primary sclerosing cholangitis, Pharmaceutical industry

BiomX Inc. (NYSE American: PHGE) (BiomX or the Company), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will receive a Therapeutics Development Award of up to $5 million from the Cystic Fibrosis Foundation (CF Foundation).

Key Points: 
  • BiomX Inc. (NYSE American: PHGE) (BiomX or the Company), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will receive a Therapeutics Development Award of up to $5 million from the Cystic Fibrosis Foundation (CF Foundation).
  • We are very pleased to receive the support of the Cystic Fibrosis Foundation an organization which historically has played a role in supporting the development of innovative therapies for patients suffering from cystic fibrosis (CF), said Jonathan Solomon, Chief Executive Officer of BiomX.
  • Under the terms of the agreement with the CF Foundation, BiomX will receive up to $5 million in two tranches.
  • In the first tranche, which closed on December 21, 2021, the CF Foundation invested $3 million as initial equity investment.